APA (7th ed.) Citation

Inarimori, K., Kakisaka, K., Watanabe, T., Sasaki, T., Fujiwara, Y., Abe, T., . . . Matsumoto, T. (2025). Autoimmune hepatitis following transition from prednisolone to thrombopoietin receptor agonist therapy in immune thrombocytopenic purpura: A clinical precaution. Hepatology Research, 55(7), 1093. https://doi.org/10.1111/hepr.14198

Chicago Style (17th ed.) Citation

Inarimori, Kaname, et al. "Autoimmune Hepatitis Following Transition from Prednisolone to Thrombopoietin Receptor Agonist Therapy in Immune Thrombocytopenic Purpura: A Clinical Precaution." Hepatology Research 55, no. 7 (2025): 1093. https://doi.org/10.1111/hepr.14198.

MLA (9th ed.) Citation

Inarimori, Kaname, et al. "Autoimmune Hepatitis Following Transition from Prednisolone to Thrombopoietin Receptor Agonist Therapy in Immune Thrombocytopenic Purpura: A Clinical Precaution." Hepatology Research, vol. 55, no. 7, 2025, p. 1093, https://doi.org/10.1111/hepr.14198.